Annexin Pharmaceuticals Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Annexin Pharmaceuticals
Access all reports
Annexin Pharmaceuticals AB (publ) is a Swedish biotechnology company that develops drug candidates for the treatment of various cardiovascular diseases. The company develops ANXV, human recombinant protein that protects and repairs blood vessels and counters inflammation. It offers Annexin A5, which is the only drug approved in Canada with this mechanism of action. The company was founded in 2014 and is based in Stockholm, Sweden.
Latest articles
Remembering Daniel Kahneman: Transforming Psychology and Economics
Explore Daniel Kahneman's legacy in psychology and economics, highlighting his impact on decision-making and behavioral economics.
28 Mar 2024
Deere & Company: Shaping Agriculture & Construction Since 1837
Exploring Deere & Company: A global leader in agriculture & construction equipment since 1837.
28 Mar 2024
Jane Fraser: First Female Leader of a Major Wall Street Bank
Discover the journey of Jane Fraser, CEO of Citigroup and the first female leader of a major Wall Street bank.
28 Mar 2024
Ticker symbol
Country
🇸🇪 Sweden